NCT06620796

A Phase II Study of Ivonescimab Combined with Cadonilimab and Chemotherapy in Extensive-stage Small Cell Lung Cancer

• Status: Not Yet Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 70 (estimated)
• Sponsor: Shanghai Pulmonary Hospital, Shanghai, China · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

The goal of this clinical trial is to investigate the efficacy, safety and tolerability of Ivonescimab combined with Cadonilimab and chemotherapy in extensive-stage small cell lung cancer patients. And also explore the potential biomarkers for predicting the efficacy of Ivonescimab combined with Cadonilimab for extensive-stage small cell lung cancer.

Conditions

• SCLC, Extensive Stage

Interventions

Type	Name	Description
DRUG	Arm 1	Ivonescimab combined with Cadonilimab plus EC
DRUG	second-line group	AK112+AK104+paclitaxel

Timeline

• Start date: 2024-09-30
• Primary completion: 2026-09-30
• Completion: 2027-09-30
• First posted: 2024-10-01
• Last updated: 2024-10-01